Previous Article | Next Article 
Infection and Immunity, November 2008, p. 4959-4967, Vol. 76, No. 11
0019-9567/08/$08.00+0 doi:10.1128/IAI.00664-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
Diminished ICAM-1 Expression and Impaired Pulmonary Clearance of Nontypeable Haemophilus influenzae in a Mouse Model of Chronic Obstructive Pulmonary Disease/Emphysema
Bing Pang,1
Wenzhou Hong,1,
Shayla L. West-Barnette,1,
Nancy D. Kock,2 and
W. Edward Swords1*
Departments of Microbiology and Immunology,1
Pathology and Comparative Medicine, Wake Forest University Health Sciences, Winston-Salem, North Carolina2
Received 28 May 2008/
Returned for modification 2 July 2008/
Accepted 3 September 2008

ABSTRACT
The airways of patients with chronic obstructive pulmonary disease
(COPD) are continually colonized with bacterial opportunists
like nontypeable
Haemophilus influenzae (NTHi), and a wealth
of evidence indicates that changes in bacterial populations
within the lung can influence the severity of COPD. In this
study, we used a murine model for COPD/emphysema to test the
hypothesis that COPD affects pulmonary clearance. Mice were
treated with a pulmonary bolus of elastase, and as reported
previously, the lungs of these mice were pathologically similar
to those with COPD/emphysema at

1 month posttreatment. Pulmonary
clearance of NTHi was significantly impaired in elastase-treated
versus mock-treated mice. While histopathologic analysis revealed
minimal differences in localized lung inflammation between the
two groups, lower levels of intercellular adhesion molecule
1 (ICAM-1) were observed for the airway epithelial surface of
elastase-treated mice than for those of control mice. Following
infection, elastase-treated mice had lung pathology consistent
with pneumonia for as long as 72 h postinfection, whereas at
the same time point, mock-treated mice had cleared NTHi and
showed little apparent pathology. Large aggregates of bacteria
were observed within damaged lung tissue of the elastase-treated
mice, whereas sparse individual bacteria were observed in lungs
of mock-treated mice at the same time point postinfection. Additional
infection studies showed that NTHi mutants with biofilm defects
were less persistent in the elastase-treated mice than the parent
strain. These findings establish a model for COPD-related infections
and support the hypotheses that ICAM-1 promotes clearance of
NTHi. Furthermore, the data indicate that NTHi may form biofilms
within the context of COPD-related infections.

INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a progressive
lung disease that includes emphysema, chronic bronchitis, and
bronchiectasis and is among the leading public health problems
worldwide (
8,
34). COPD affects over 10 million adults in the
United States alone (
22) and is the fourth leading cause of
death in the United States (
13). The estimated total economic
impact of COPD in the United States is over $20 billion/year
(
44). While the primary cause of COPD is smoking or exposure
to other inhaled pollutants, the progression and severity of
COPD may be promoted by opportunistic airway infections (
37).
While this has been an area of some controversy (
9), it is undeniable
that the management of COPD is, at best, seriously complicated
by bacterial and viral infections (
31). The agents that cause
COPD-related airway infections are found predominantly within
the normal flora of the nasopharynx and include nontypeable
Haemophilus influenzae (NTHi),
Streptococcus pneumoniae,
Moraxella catarrhalis, and
Pseudomonas aeruginosa (
25,
26,
37,
38). Patients
may also be chronically infected with
H. haemolyticus, which
does not seem to be a significant pathogen but is associated
with asymptomatic carriage (
27). In patients with COPD, carriage
of these organisms is not limited to the nasopharynx, as is
the case in healthy patients, but extends into the upper and
lower airways (
23,
24,
29).
The composition of the bacterial population within the COPD lung is extremely dynamic, with individual strains/clones exhibiting variable persistence and with incoming strains supplanting other strains (35-39). Patients with COPD can be colonized by several different strains simultaneously, and the length of persistence varies dramatically between the different strains (30). Patient studies have demonstrated that some strains of NTHi can persist within individual patients for months or even years and that exacerbations of COPD are significantly correlated with the acquisition of a new bacterial strain (35, 36, 39), apparently independently of the bacterial load (39) but in accordance with host-pathogen interactions that may be specific to the individual bacterial strain (3). Notably, most animal models for pulmonary infection fail to mimic the degree of bacterial persistence observed for human patients. For example, it is well established that mice that receive a pulmonary infection of NTHi reproducibly clear the infection within 4 days postinoculation (33, 49, 50). There is a need for an animal model that better reflects the persistent infections that occur in the context of COPD.
One of the hallmarks of COPD/emphysema is tissue destruction by elastase released by neutrophils within the lung, resulting in pulmonary fibrin deposition and decreased lung volume (41, 42). In prior studies, COPD-like conditions have been established in mice by chronic exposure to cigarette smoke (40-42) or by the introduction of a bolus of elastase into the lung (15, 20, 32). In the latter model, mice treated with elastase exhibited lung damage consistent with COPD, including tissue destruction within the lung, enlargement of airspaces, and fibrotic deposits within the lung alveolar spaces. We reasoned that this model system could provide a better way to examine bacterial clearance from the COPD lung. Therefore, we compared bacterial clearance following pulmonary infection with NTHi in mice treated with elastase with that of controls treated with vehicle (phosphate-buffered saline [PBS]) alone. The results show that clearance of NTHi from the lung was significantly impaired following elastase treatment, in accordance with the formation of large bacterial communities that were not observed for the control mice. Furthermore, immunohistochemical analysis revealed diminished expression of intercellular adhesion molecule 1 (ICAM-1) on the airway epithelial surfaces of the elastase-treated mice following infection compared to that of the control groups. We thus conclude that pulmonary infections in mice with normal clearance may not fully represent the host-pathogen interactions that determine the outcome of infections in COPD and that the outcome of a pulmonary bacterial infection in this setting may be determined by the interplay of host clearance events initiated by ICAM-1 expression on the airway epithelium and by bacterial persistence mechanisms that may include biofilm formation.

MATERIALS AND METHODS
Bacterial strains and growth conditions.
All NTHi strains were cultivated on supplemented brain-heart
infusion (Difco) medium supplemented with NAD (Sigma) and hemin
(ICN), as described previously (
45-
48). NTHi 2019 is a well-characterized
strain that was originally isolated from the sputum of a patient
with chronic bronchitis (
2), and all of the mutant strains were
derived from this strain background. A list of bacterial strains,
along with primary references and phenotypes, is provided in
Table
1.
Elastase treatment.
Healthy C57BL/6 mice were purchased from Charles River Laboratories
(Wilmington, MA). Mice were anesthetized with Avertin (2,2,2-tribromoethanol),
and a 50-µl bolus of elastase (Sigma) suspended in sterile
PBS was instilled intratracheally into the lung. The amount
of elastase used was determined by dose-response experiments
as the minimal amount of enzyme necessary to generate lung damage
consistent with COPD. Various doses of elastase (1 to 9 units)
were intratracheally instilled into mice (five/group), and the
mice were then euthanized 21 days posttreatment. Histopathologic
analysis revealed tissue fibrosis and reduction in airway space,
consistent with COPD, at 3, 6, and 9 U of elastase (data not
shown), with no apparent pathology in mice that received vehicle
(PBS) alone (Fig.
1 and
2). As 3 U of elastase was the minimal
dose needed to elicit COPD-like pathology, this was the amount
chosen for infection studies. Animals were allowed to recover
for 21 days after elastase treatment, before histopathology
and/or infection studies were performed.
Infections.
NTHi bacteria were harvested from overnight plate cultures and
suspended in PBS. Bacterial counts were estimated by optical
density and suspended in PBS solution as described previously
(
45). The estimated bacterial density was confirmed by plate
count. Approximately 10
7 CFU was used to infect mice (five animals/group).
The mice were anesthetized as described before and infected
intratracheally, and the bacterial load in the inocula was confirmed
by plate count. At the times indicated, mice were euthanized,
and their lungs were excised. For each animal, the left lung
was homogenized and used for plate count. Plate count data were
analyzed by unpaired
t test analysis with Welch's correction
for unequal variance; groups with
P values of less than 0.05
were deemed significantly different from the control. The right
lungs were fixed in 4% paraformaldehyde-PBS for histopathology
and cryosection. The elastase treatment and infection protocols
were approved by the Wake Forest University Health Sciences
animal care and use committee.
Histopathology.
Portions of fixed lung tissue were dehydrated and embedded in paraffin according to standard methods. Sections (5 µm) were cut from paraffin-embedded blocks with a microtome and mounted from warm water (40°C) onto adhesive microscope slides. After serial deparaffinization and rehydration, tissue sections were stained with hematoxylin and eosin for histopathologic assessment. Stained slides were provided as a blinded set to a veterinary pathologist (N.K.) and were scored for markers of inflammation (neutrophilic influx, edema, etc.).
Immunostaining.
To determine ICAM-1 expression, paraffin sections were stained using monoclonal antibody 3E2, recognizing mouse ICAM-1 (BD Pharmingen) according to the manufacturer's instructions, essentially as reported by others (6). For visualization of NTHi bacteria, portions of fixed lung tissue samples were rinsed with 1x PBS at room temperature and placed into a Cryomold (Sakura Finetek USA, Torrance, CA). Tissue-Tek OCT compound (Sakura Finetek USA, Torrance, CA) was added, and the blocks were frozen at –70°C for 1 h. Serial 5-µm sections were cut using an Accu-Edge low-profile blade (Feather Safety Razor Co., Japan) at –20°C and stored at –70°C. Immunofluorescence staining was performed using rabbit antisera recognizing NTHi, essentially as described previously (33). For both sets of sections, pixel quantization was performed for all tissue sections and is presented as the mean numbers of pixels for ICAM-1 or bacterial staining.

RESULTS
Pulmonary elastase treatment results in damage consistent with COPD/emphysema and impaired bacterial clearance.
To elicit pulmonary fibrotic damage consistent with COPD, mice
were treated with a pulmonary bolus of elastase, vehicle (PBS),
or heat-inactivated elastase delivered via nonsurgical intratracheal
instillation. After 21 days, mice in each group were euthanized,
and their lungs were sectioned and stained with hematoxylin
and eosin for histopathologic analysis. The results clearly
showed significant pulmonary damage in the elastase-treated
mice, whereas there was minimal damage observed for the control
groups (Fig.
1).
The effect of this treatment on the clearance of NTHi strain 2019 from the lung was determined with pulmonary infection studies using elastase-treated mice and mock-treated mice. While bacterial counts obtained from lung homogenates were comparable at an early time point (6 h postinfection), significantly higher numbers of bacteria were recovered from the elastase-treated mice at 24 h, 48 h, and 72 h postinfection (Fig. 2). In the control group, the numbers of bacteria declined significantly over time, and the majority of mice had pulmonary bacterial loads below the threshold of detection by 72 h postinfection. Thus, we concluded that mice treated with elastase had impaired pulmonary clearance of NTHi.
Histopathologic analysis of lung tissue from infected mice.
Lung tissue from each group of mice was embedded in paraffin, sectioned, and stained for histopathologic assessment (as described in Materials and Methods). Stained slides were examined as a blinded set by a veterinary pathologist (N.K.) and scored for parameters of airway inflammation, which were compiled into a total score for inflammation. Figure 3 shows representative images from each group at the different time points postinfection. Notably, there was a dramatic loss of alveolar lung tissue, along with fibrosis, observed for the elastase-treated mice even prior to infection (Fig. 3C to E). Localized tissue responses, including edema and cellular infiltrate that included neutrophils, were observed for both groups of animals. Total histopathology scores were compiled for each group of sections as blinded sets. The only differences in scoring occurred with samples from the latest time point (72 h postinfection), where inflammation remained notable in the elastase-treated group. In contrast, all indicators of inflammation were decreased in the mock-treated group at this time-point (Fig. 3F to G). As shown in Fig. 2, elastase-treated mice failed to clear NTHi bacteria from the lung within 72 h postinfection. For the mock-treated mice, epithelial cells were observed sloughed into a bronchiolar lumen, and the interstitium was mildly infiltrated by neutrophils. In contrast, the sections from the elastase-treated mice showed severe pneumonia with marked infiltration of neutrophils, causing consolidation of the lung.
Histopathology scores.
The stained sections were examined as a blinded set and assigned
scores (
1-
4) for markers of inflammation. A composite score
(
1-
10) was compiled based on the total scores. The results are
depicted in Fig.
4. A significant increase in vascular degeneration
was observed in the elastase treatment group early after infection
(Fig.
4A). Bronchial epithelial responses peaked later and to
a greater degree in the elastase treatment group (Fig.
4B),
as was observed for pneumonia (Fig.
4C), alveolar macrophages
(Fig.
4D), and airway inflammation (Fig.
4E). Similarly, the
composite inflammation scores were higher for the elastase treatment
group at the later time points postinfection (Fig.
4F). No significant
differences were noted in the number of total lymphocytes (data
not shown). Taken together, these results indicate a slower
pulmonary inflammatory response that reached higher levels later
after infection for the elastase treatment group.
Diminished surface expression of ICAM-1 in elastase-treated mice.
ICAM-1 is expressed on the airway epithelial surface under many
different pulmonary inflammatory conditions and serves to facilitate
neutrophil recruitment into the lung (
4,
7,
51,
52). Surface
expression of ICAM-1 has been demonstrated to promote NTHi clearance
from mouse lung (
6), although there are also indications that
NTHi may utilize ICAM-1 as a receptor for attachment to epithelial
surfaces (
1). Therefore, we determined whether ICAM-1 expression
was altered in the elastase-treated mice. Paraffin sections
of lung tissue from infected mice were examined by immunostaining
for ICAM-1. Figure
5 shows representative images from light
microscopic examination of tissue from each group of animals,
along with quantization of ICAM-1 staining as a percentage of
total pixels in all sections. In the control group, ICAM-1 expression
increased significantly as early as 6 h postinfection and remained
elevated above the baseline throughout the infection study.
However, the level of expression in the elastase-treated animals
was markedly lower at all time points and did not show an increase
until 24 to 48 h postinfection. Therefore, based on these data,
we conclude that ICAM-1 expression is diminished and temporally
changed in the elastase-treated mice.
Presence of multicellular NTHi bacterial communities within the lungs of elastase-treated mice.
To visualize NTHi bacteria within the lungs of infected mice,
cryosections were prepared from mock-treated and elastase-treated
mice at the various time points after infection and stained
with polyclonal rabbit antisera directed against NTHi. For mock-treated
animals, limited reactivity was observed that correlated in
size with individual bacteria dispersed throughout the lung
tissue taken 48 h postinfection (Fig.
6A). However, in the elastase-treated
animals, larger regions of reactivity were visible in discrete
locations within the lung tissue at this time point (Fig.
6B).
Quantization of the fluorescence from microscopy images from
all infection groups showed an

40-fold increase in bacterial
density within the lung tissue of elastase-treated mice at this
time point (Fig.
6). Examination of sections at a higher magnification
revealed that these regions were more than 10 µm in diameter,
which correlates in size with a multicellular community of NTHi
bacteria (Fig.
6C). Moreover, as clearly visible by differential
interference contrast/Nomarski imaging, the NTHi communities
were present in damaged regions of the lung with fibrotic deposits.
Paired histopathologic staining of serial sections immediately
adjacent to those stained for immunofluorescence revealed the
presence of neutrophils surrounding many of these communities
(Fig.
6C).
Infection studies using mutant NTHi strains.
To further clarify the role(s) of specific persistence-related
surface moieties in NTHi persistence within the elastase-treated
mice, we performed infection studies using a panel of mutant
strains (Fig.
7). For the purpose of comparison, we chose the
48-h time point postinfection, as bacteria were consistently
recovered from both the control and elastase-treated mice with
maximal differences at this time point. As in the initial studies
shown in Fig.
1, significantly higher numbers of NTHi 2019 bacteria
were recovered from elastase-treated mice. However, the counts
from control and elastase-treated mice infected with a sialylated
(
siaB) mutant strain were indistinguishable. Similarly, counts
from mice infected with a "rough" mutant lacking the oligosaccharide
portion of the LOS moiety (
pgmB mutant) or with mutants with
altered expression of phosphorylcholine-positive lipooligosaccharides
(
licD and
licON mutants, the latter harboring an in-frame deletion
of the CAAT repeat region in
licA), were indistinguishable between
the control and elastase-treatment groups. However, mice infected
with the NTHi 2019
htrB strain, which has an underacylated lipid
A, had significantly higher resistance to clearance in the elastase-treated
group than in the control group, similar to the parental strain.
It is notable that all of the mutations that affected the persistence
of the elastase treatment group affected the oligosaccharide
portion of the lipooligosaccharides on the NTHi surface. Therefore,
based on these data, we conclude that moieties contained within
the carbohydrate portion of the endotoxins on the NTHi surface
promote persistence within elastase-treated mice. The implications
of these data for the role(s) of biofilms in the increased persistence
phenotype will be further outlined in the discussion.

DISCUSSION
While it is clear that patients with COPD/emphysema have increased
susceptibility to many respiratory pathogens, there remains
a need for a better understanding of the mechanisms for this
susceptibility. In this study, we adapted an existing model
of COPD for infection studies. The results clearly show that
following pulmonary treatment with elastase to elicit a COPD-like
condition, mice had a significant clearance defect for NTHi
bacteria compared to mock-treated mice. This clearance defect
was correlated with a delayed expression of ICAM-1 on the airway
epithelial surfaces, a host response that promotes the influx
of neutrophils and the resolution of NTHi infection (
6). It
is notable that the basal level of ICAM-1 expression observed
for the elastase-treated mice was significantly higher than
that observed for mock-treated mice. ICAM-1 appears to play
several roles in NTHi and viral infection, including not only
an essential role in the clearance of pathogens but also as
a receptor for bacterial and viral adherence (
1). Thus, it is
possible that the low-level, diffuse expression of ICAM-1 in
the elastase-treated mice served to facilitate bacterial adherence
to the damaged epithelial surfaces within the damaged regions
of the lung, in addition to the observed delay in pulmonary
inflammation and neutrophilic influx Therefore, our results
may be consistent with multiple roles for ICAM-1 expression
in pulmonary infection with NTHi.
The presence of multicellular NTHi communities observed within the lung tissue of the elastase-treated mice also merits comment. Like many mucosal pathogens, NTHi bacteria form biofilms during chronic infections, and we and other groups have demonstrated that these biofilms are correlated with bacterial resistance to clearance in vivo (10, 11, 17-19, 48). Murphy and colleagues have demonstrated that NTHi peroxiredoxin is found within sputa and other samples from patients with COPD (28). Since peroxiredoxin has increased expression in NTHi biofilms, these results were suggestive of a biofilm mode of growth for NTHi within the COPD lung. Our work has demonstrated that the presence of specific lipooligosaccharide glycoforms containing sialic acid and phosphorylcholine promotes biofilm formation in laboratory models, as well as in animal models (10, 11, 48). Thus, the finding that the parental strain has enhanced persistence within the elastase-treated mouse lung, whereas sialylated and phosphorylcholine-deficient bacteria do not, is consistent with a key role for biofilm formation in this phenotype. Likewise, the pgmB mutant, lacking all oligosaccharide structures, is sialylated and has a biofilm defect in vivo (19). Alternative explanations for the persistence defects observed for these strains include more efficient killing by complement or other bactericidal host factors, which has been reported for the siaB mutants (5, 12, 19). If this were the case, one would expect a more severe defect in the control group than was observed. On that note, the results obtained with the htrB mutant are somewhat surprising given this strain's susceptibility to defensins in the lung (43, 46). Regardless, these data clearly point toward the oligosaccharide portion of the lipooligosaccharide as a determinant of resistance to clearance in the mouse COPD model system. It is also noteworthy that no enhancement was seen in the infection studies with the licON mutant strain (Fig. 7). Whereas our prior work has clearly demonstrated that this strain has increased biofilm density (11), it is also clear that in some disease settings, not only the presence but the phase variation of the lic1 system is required (14). This may indicate that phosphorylcholine is advantageous only within certain windows of the disease process. Furthermore, it should be noted that the requirements for persistence and/or virulence within the lung and middle ear may be subtly or even dramatically different.
In summary, we have used a mouse model for COPD to demonstrate that ICAM-1 expression by the host and biofilm formation by the pathogen are important in determining the outcome of pulmonary infections with NTHi in the context of experimental COPD in a murine model. As the availability of a relevant animal model has been lacking for COPD-related infections, the results of this study provide a means to test the biofilm hypothesis as well as other fundamental hypotheses regarding the role of opportunistic pathogens in the exacerbation of COPD.

ACKNOWLEDGMENTS
We acknowledge excellent technical assistance by Gayle Foster
and helpful conversations with colleagues in the WFUHS Department
of Microbiology and Immunology.
This work was supported by a grant from NIH/NIAID (AI054425; to W.E.S.).
Shayla West-Barnette was supported by an individual NIH fellowship (AI061830).

FOOTNOTES
* Corresponding author. Mailing address: 5101A Gray Building, Medical Center Boulevard, Winston-Salem, NC 27157. Phone: (336) 713-5049. Fax: (336) 716-9928. E-mail:
wswords{at}wfubmc.edu 
Published ahead of print on 15 September 2008. 
Editor: J. N. Weiser
Present address: Department of Otolaryngology, Medical College of Wisconsin, Milwaukee, WI. 
Present address: NIDCD/NIH, Bethesda, MD. 

REFERENCES
1 - Avadhanula, V., C. A. Rodriguez, G. C. Ulett, L. O. Bakaletz, and E. E. Adderson. 2006. Nontypeable Haemophilus influenzae adheres to intercellular adhesion molecule 1 (ICAM-1) on respiratory epithelial cells and upregulates ICAM-1 expression. Infect. Immun. 74:830-838.[Abstract/Free Full Text]
2 - Campagnari, A. A., M. R. Gupta, K. C. Dudas, T. F. Murphy, and M. A. Apicella. 1987. Antigenic diversity of lipooligosaccharides of nontypeable Haemophilus influenzae. Infect. Immun. 55:882-887.[Abstract/Free Full Text]
3 - Chin, C. L., L. J. Manzel, E. E. Lehman, A. L. Humlicek, L. Shi, T. D. Starner, G. M. Denning, T. F. Murphy, S. Sethi, and D. C. Look. 2005. Haemophilus influenzae from patients with chronic obstructive pulmonary disease exacerbation induce more inflammation than colonizers. Am. J. Respir. Crit. Care Med. 172:85-91.[Abstract/Free Full Text]
4 - Churchill, L., R. H. Gundel, L. G. Letts, and C. D. Wegner. 1993. Contribution of specific cell-adhesive glycoproteins to airway and alveolar inflammation and dysfunction. Am. Rev. Respir. Dis. 148:S83-S87.[Medline]
5 - Figueira, M. A., S. Ram, R. Goldstein, D. W. Hood, E. R. Moxon, and S. I. Pelton. 2007. Role of complement in defense of the middle ear revealed by restoring the virulence of nontypeable Haemophilus influenzae siaB mutants. Infect. Immun. 75:325-333.[Abstract/Free Full Text]
6 - Frick, A. G., T. D. Joseph, L. Pang, A. M. Rabe, J. W. St. Geme III, and D. C. Look. 2000. Haemophilus influenzae stimulates ICAM-1 expression on respiratory epithelial cells. J. Immunol. 164:4185-4196.[Abstract/Free Full Text]
7 - Gundel, R. H., C. D. Wegner, C. A. Torcellini, and L. G. Letts. 1992. The role of intercellular adhesion molecule-1 in chronic airway inflammation. Clin. Exp. Allergy 22:569-575.[CrossRef][Medline]
8 - Halbert, R. J., J. L. Natoli, A. Gano, E. Badamgarav, A. S. Buist, and D. M. Mannino. 2006. Global burden of COPD: systematic review and meta-analysis. Eur. Respir. J. 28:523-532.[Abstract/Free Full Text]
9 - Hirschmann, J. V. 2000. Do bacteria cause exacerbations of COPD? Chest 118:193-203.[CrossRef][Medline]
10 - Hong, W., K. Mason, J. A. Jurcisek, L. A. Novotny, L. O. Bakaletz, and W. E. Swords. 2007. Phosphorylcholine decreases early inflammation and promotes the establishment of stable biofilm communities of nontypeable Haemophilus influenzae strain 86-028NP in a chinchilla model of otitis media. Infect. Immun. 75:958-965.[Abstract/Free Full Text]
11 - Hong, W., B. Pang, S. West-Barnette, and W. E. Swords. 2007. Phosphorylcholine expression by nontypeable Haemophilus influenzae correlates with maturation of biofilm communities in vitro and in vivo. J. Bacteriol. 189:8300-8307.[Abstract/Free Full Text]
12 - Hood, D. W., K. Makepeace, M. E. Deadman, R. F. Rest, P. Thibault, A. Martin, J. C. Richards, and E. R. Moxon. 1999. Sialic acid in the lipopolysaccharide of Haemophilus influenzae: strain distribution, influence on serum resistance and structural characterization. Mol. Microbiol. 33:679-692.[CrossRef][Medline]
13 - Hoyert, D. L., E. Arias, B. L. Smith, S. L. Murphy, and K. D. Kochanek. 2001. Deaths: final data for 1999. Natl. Vital Stat. Rep. 49:1-113.[Medline]
14 - Humphries, H. E., and N. J. High. 2002. The role of licA phase variation in the pathogenesis of invasive disease by Haemophilus influenzae type b. FEMS Immunol. Med. Microbiol. 34:221-230.[CrossRef][Medline]
15 - Inoue, S., H. Nakamura, K. Otake, H. Saito, K. Terashita, J. Sato, H. Takeda, and H. Tomoike. 2003. Impaired pulmonary inflammatory responses are a prominent feature of streptococcal pneumonia in mice with experimental emphysema. Am. J. Respir. Crit. Care Med. 167:764-770.[Abstract/Free Full Text]
16 - Jones, P. A., N. A. Samuels, N. J. Phillips, R. S. Munson, J. A. Bozue, J. A. Arseneau, W. A. Nichols, A. Zaleski, B. W. Gibson, and M. A. Apicella. 2002. Haemophilus influenzae type B strain A2 has multiple sialyltransferases involved in lipooligosaccharide sialylation. J. Biol. Chem. 277:14598-14611.[Abstract/Free Full Text]
17 - Jurcisek, J. A., and L. O. Bakaletz. 2007. Biofilms formed by nontypeable Haemophilus influenzae in vivo contain both double-stranded DNA and type IV pilin protein. J. Bacteriol. 189:3868-3875.[Abstract/Free Full Text]
18 - Jurcisek, J. A., J. Bookwalter, B. Baker, S. Fernandez, L. A. Novotny, R. S. Munson, Jr., and L. O. Bakaletz. 2007. The PilA protein of nontypeable Haemophilus influenzae plays a role in biofilm formation, adherence to epithelial cells and colonization of the mammalian upper respiratory tract. Mol. Microbiol. 65:1288-1299.[CrossRef][Medline]
19 - Jurcisek, J. A., L. Greiner, H. Watanabe, A. Zaleski, M. A. Apicella, and L. O. Bakaletz. 2005. Role of sialic acid and complex carbohydrate biosynthesis in biofilm formation by nontypeable Haemophilus influenzae in the chinchilla middle ear. Infect. Immun. 73:3210-3218.[Abstract/Free Full Text]
20 - Karlinsky, J. B., and G. L. Snider. 1978. Animal models of emphysema. Am. Rev. Respir. Dis. 117:1109-1133.[Medline]
21 - Lee, N.-G., M. G. Sunshine, J. J. Engstrom, B. W. Gibson, and M. A. Apicella. 1995. Mutation of the htrB locus of Haemophilus influenzae nontypeable strain 2019 is associated with modifications of lipid A and phosphorylation of the lipo-oligosaccharide. J. Biol. Chem. 270:27151-27159.[Abstract/Free Full Text]
22 - Mannino, D. M., D. M. Homa, L. J. Akinbami, E. S. Ford, and S. C. Redd. 2002. Chronic obstructive pulmonary disease surveillance-United States, 1971-2000. MMWR Surveill Summ. 51:1-16.[Medline]
23 - Monso, E., J. Ruiz, A. Rosell, J. Manterola, J. Fiz, J. Morera, and V. Ausina. 1995. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am. J. Respir. Crit. Care Med. 152:1316-1320.[Abstract]
24 - Murphy, T. F. 2000. Haemophilus influenzae in chronic bronchitis. Semin. Respir. Infect. 15:41-51.[Medline]
25 - Murphy, T. F., A. L. Brauer, K. Eschberger, P. Lobbins, L. Grove, X. Cai, and S. Sethi. 2008. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 177:491-497.[Abstract/Free Full Text]
26 - Murphy, T. F., A. L. Brauer, A. T. Schiffmacher, and S. Sethi. 2004. Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 170:266-272.[Abstract/Free Full Text]
27 - Murphy, T. F., A. L. Brauer, S. Sethi, M. Kilian, X. Cai, and A. J. Lesse. 2007. Haemophilus haemolyticus: a human respiratory tract commensal to be distinguished from Haemophilus influenzae. J. Infect. Dis. 195:81-89.[CrossRef][Medline]
28 - Murphy, T. F., C. Kirkham, S. Sethi, and A. Lesse. 2005. Expression of a peroxiredoxin-glutaredoxin by Haemophilus influenzae in bioflims and during human respiratory tract infection. FEMS Immunol. Med. Microbiol. 44:81-89.[CrossRef][Medline]
29 - Murphy, T. F., and S. Sethi. 1992. Bacterial infection in chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 146:1067-1083.[Medline]
30 - Murphy, T. F., S. Sethi, K. L. Klingman, A. B. Brueggemann, and G. V. Doern. 1999. Simultaneous respiratory tract colonization by multiple strains of nontypeable Haemophilus influenzae in chronic obstructive pulmonary disease: implications for antibiotic therapy. J. Infect. Dis. 180:404-409.[CrossRef][Medline]
31 - Murphy, T. F., S. Sethi, and M. S. Niederman. 2000. The role of bacteria in exacerbations of COPD. A constructive view. Chest 118:204-209.[CrossRef][Medline]
32 - Otto-Verberne, C. J., A. A. Ten Have-Opbroek, C. Franken, J. Hermans, and J. H. Dijkman. 1992. Protective effect of pulmonary surfactant on elastase-induced emphysema in mice. Eur. Respir. J. 5:1223-1230.[Abstract]
33 - Pang, B., D. Winn, R. Johnson, W. Hong, S. West-Barnette, N. Kock, and W. E. Swords. 2008. Lipooligosaccharides containing phosphorylcholine delay pulmonary clearance of nontypeable Haemophilus influenzae. Infect. Immun. 76:2037-2043.[Abstract/Free Full Text]
34 - Rennard, S. I. 1998. COPD: overview of definitions, epidemiology, and factors influencing its development. Chest 113(Suppl.):235S-241S.[CrossRef][Medline]
35 - Sethi, S., N. Evans, B. J. Grant, and T. F. Murphy. 2002. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 347:465-471.[Abstract/Free Full Text]
36 - Sethi, S., J. Maloney, L. Grove, C. Wrona, and C. S. Berenson. 2006. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 173:991-998.[Abstract/Free Full Text]
37 - Sethi, S., and T. F. Murphy. 2001. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin. Microbiol. Rev. 14:336-363.[Abstract/Free Full Text]
38 - Sethi, S., R. Sethi, K. Eschberger, P. Lobbins, X. Cai, B. J. Grant, and T. F. Murphy. 2007. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 176:356-361.[Abstract/Free Full Text]
39 - Sethi, S., C. Wrona, K. Eschberger, P. Lobbins, X. Cai, and T. F. Murphy. 2007. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.
40 - Shapiro, S. D. 2002. Neutrophil elastase: path clearer, pathogen killer, or just pathologic? Am. J. Respir. Cell Mol. Biol. 26:266-268.[Free Full Text]
41 - Shapiro, S. D. 1995. The pathogenesis of emphysema: the elastase:antielastase hypothesis 30 years later. Proc. Assoc. Am. Physicians 107:346-352.[Medline]
42 - Shapiro, S. D., N. M. Goldstein, A. M. Houghton, D. K. Kobayashi, D. Kelley, and A. Belaaouaj. 2003. Neutrophil elastase contributes to cigarette smoke-induced emphysema in mice. Am. J. Pathol. 163:2329-2335.[Abstract/Free Full Text]
43 - Starner, T. D., W. E. Swords, M. A. Apicella, and P. B. McCray, Jr. 2002. Susceptibility of nontypeable Haemophilus influenzae to human β-defensins is influenced by lipooligosaccharide acylation. Infect. Immun. 70:5287-5289.[Abstract/Free Full Text]
44 - Sullivan, S. D., S. D. Ramsey, and T. A. Lee. 2000. Economic burden of COPD. Chest 117:5S-9S.[CrossRef][Medline]
45 - Swords, W. E., B. Buscher, K. Ver Steeg, W. Nichols, A. Preston, J. N. Weiser, B. Gibson, and M. A. Apicella. 2000. Nontypeable Haemophilus influenzae adhere to and invade human bronchial epithelial cells by an interaction of lipooligosaccharide with the PAF receptor. Mol. Microbiol. 37:13-27.[CrossRef][Medline]
46 - Swords, W. E., D. L. Chance, L. A. Cohn, J. Shao, M. A. Apicella, and A. L. Smith. 2002. Acylation of the lipooligosaccharide of Haemophilus influenzae and colonization: an htrB mutation diminishes the colonization of human airway epithelial cells. Infect. Immun. 70:4661-4668.[Abstract/Free Full Text]
47 - Swords, W. E., M. R. Ketterer, J. Shao, C. A. Campbell, J. N. Weiser, and M. A. Apicella. 2001. Binding of the nontypeable Haemophilus influenzae lipooligosaccharide to the PAF receptor initiates host cell signaling. Cell Microbiol. 8:525-536.
48 - Swords, W. E., M. L. Moore, L. Godzicki, G. Bukofzer, M. J. Mitten, and J. VonCannon. 2004. Sialylation of lipooligosaccharides promotes biofilm formation by nontypeable Haemophilus influenzae. Infect. Immun. 72:106-113.[Abstract/Free Full Text]
49 - Toews, G. B., D. A. Hart, and E. J. Hansen. 1985. Effect of systemic immunization on pulmonary clearance of Haemophilus influenzae type b. Infect. Immun. 48:343-349.[Abstract/Free Full Text]
50 - Toews, G. B., S. Viroslav, D. A. Hart, and E. J. Hansen. 1984. Pulmonary clearance of encapsulated and unencapsulated Haemophilus influenzae strains. Infect. Immun. 45:437-442.[Abstract/Free Full Text]
51 - Tosi, M. F., J. M. Stark, C. W. Smith, A. Hamedani, D. C. Gruenert, and M. D. Infeld. 1992. Induction of ICAM-1 expression on human airway epithelial cells by inflammatory cytokines: effects on neutrophil-epithelial cell adhesion. Am. J. Respir. Cell Mol. Biol. 7:214-221.[Medline]
52 - Wegner, C. D., R. H. Gundel, P. Reilly, N. Haynes, L. G. Letts, and R. Rothlein. 1990. Intercellular adhesion molecule-1 (ICAM-1) in the pathogenesis of asthma. Science 247:456-459.[Abstract/Free Full Text]
53 - West-Barnette, S., A. Rockel, and W. E. Swords. 2006. Biofilm growth increases phosphorylcholine content and decreases potency of nontypeable Haemophilus influenzae endotoxins. Infect. Immun. 74:1828-1836.[Abstract/Free Full Text]
Infection and Immunity, November 2008, p. 4959-4967, Vol. 76, No. 11
0019-9567/08/$08.00+0 doi:10.1128/IAI.00664-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.